GLP-1 Lawsuit (2026): Where the Ozempic, Wegovy, Mounjaro and Zepbound Cases Stand
The lawsuits against Ozempic and the other GLP-1 drugs are consolidated in a federal MDL in Philadelphia - about 3,900 cases over stomach paralysis and bowel obstruction, plus a newer vision-loss MDL. No settlement exists. Here is the verified status, what injuries qualify, and what happens next.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Allege
Plaintiffs allege that Novo Nordisk (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda) and Eli Lilly (Mounjaro, Zepbound, Trulicity) failed to adequately warn of severe gastrointestinal injuries - above all gastroparesis (stomach paralysis; about three-quarters of claims per trackers), ileus/bowel obstruction, and gallbladder injury, with pancreatitis and kidney injury also pleaded. A separate track alleges NAION - sudden optic-nerve vision loss - after a July 2024 JAMA Ophthalmology study reported 4.3× (diabetes) to 7.6× (weight-loss) higher risk. Both manufacturers deny the allegations.
Case Details
MDL 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, Eastern District of Pennsylvania, Judge Karen S. Marston (created February 2024). NAION claims were spun into MDL 3163 (December 2025), same court and judge. A New Jersey multicounty litigation runs in parallel (November 2025).
Status as of August 2026
Who the Lawsuits Cover
Typical criteria firms screen for (intake rules, not court standards):
• Use of a GLP-1 drug - Ozempic, Wegovy, Rybelsus, Victoza, Saxenda (Novo) or Mounjaro, Zepbound, Trulicity (Lilly)
• A diagnosed qualifying injury: gastroparesis confirmed by gastric-emptying study (per the 2025 ruling), ileus/bowel obstruction, gallbladder injury, pancreatitis - or NAION for the vision-loss MDL
• Medical treatment for the injury (hospitalization strengthens claims)
• Use for diabetes or for weight loss both qualify
The FDA updated at least one GLP-1 label in October 2025 to advise against use in severe gastroparesis; the EMA added NAION as a very rare side effect in June 2025, while the FDA had not mandated a NAION warning as of August 2026.
Compensation - What's Real and What's Projection
GLP-1 Litigation Timeline
- 1
2023 — First Gastroparesis Suits
Individual lawsuits allege stomach paralysis and bowel obstruction after Ozempic and Mounjaro use.
- 2
February 2024 — MDL 3094 Created
The JPML consolidates federal GLP-1 cases in the Eastern District of Pennsylvania before Judge Karen Marston.
- 3
August 15, 2025 — Gastroparesis Proof Ruling
Gastric-emptying study required for gastroparesis diagnoses; design-defect claims dismissed; failure-to-warn survives.
- 4
December 2025 — NAION Gets Its Own MDL (3163)
Vision-loss claims are separated for coordinated pretrial handling; Science Day held June 2, 2026, early causation discovery ordered July 2, 2026.
- 5
September 10-18, 2026 — Rule 702 Hearing
Expert-admissibility hearing on causation, warnings and preemption - the pivotal event of 2026; first bellwethers projected afterward.
Watch Out For
Three things to be skeptical of:
'$2 billion Ozempic settlement' posts
There is no settlement. Fact-checkers have debunked viral claims; the MDL is in pretrial proceedings.
Quoted payout ranges presented as fact
Every dollar figure circulating is a firm's projection. Nothing has been paid to anyone.
Self-diagnosed gastroparesis
Since August 2025 the court requires a gastric-emptying study. Nausea alone, or a diagnosis without the study, will not carry a claim.
GLP-1 Lawsuit - FAQ
Is there a lawsuit against Ozempic?
Yes - thousands of lawsuits against Ozempic and other GLP-1 drugs are consolidated in MDL 3094 (E.D. Pa.), with NAION vision-loss claims in MDL 3163. About 3,900 and ~200 cases respectively as of August 2026.
Which drugs are in the GLP-1 lawsuit?
Novo Nordisk's Ozempic, Wegovy, Rybelsus, Victoza and Saxenda, and Eli Lilly's Mounjaro, Zepbound and Trulicity.
Has anyone been paid yet?
No. There are no settlements or verdicts in either MDL as of August 2026. Dollar ranges online are projections.
What injuries qualify?
Gastroparesis (with a gastric-emptying study), ileus/bowel obstruction, gallbladder injury, pancreatitis, kidney injury - and NAION vision loss in the separate MDL.
What happens in September 2026?
The Rule 702 hearing (Sept 10-18) decides whether plaintiffs' causation experts can testify - the gatekeeping ruling that shapes everything after it.
When will the GLP-1 lawsuit settle?
No date. Trackers project first bellwether trials late 2026 at the earliest and broad resolution not before late 2027. Anyone quoting a date is guessing.
Is the NAION (vision loss) claim strong?
It is newer and scientifically contested: a 2024 JAMA Ophthalmology study found elevated risk, the EMA added a label warning in 2025, the FDA had not by August 2026. Early causation discovery is under way; bellwethers are years off.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.